The average price point forecasted by analysts for Inovio Pharmaceuticals Inc (INO) is $0.40, which is -$0.01 below the current market price. The public float for INO is 268.55M, and currently, short sellers hold a 9.29% ratio of that float. The average trading volume of INO on November 20, 2023 was 3.47M shares.

INO) stock’s latest price update

The stock of Inovio Pharmaceuticals Inc (NASDAQ: INO) has decreased by -5.48 when compared to last closing price of 0.43. Despite this, the company has experienced a 15.89% gain in its stock price over the last five trading sessions. InvestorPlace reported 2023-11-14 that These companies in the biotechnology sector are doing incredible work and achieving wonderful developments. The result is not not only growth and profit for the companies, but they are also offering excellent and efficient solutions for the health of each one of us.

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


INO’s Market Performance

Inovio Pharmaceuticals Inc (INO) has seen a 15.89% rise in stock performance for the week, with a -13.70% decline in the past month and a -8.85% plunge in the past quarter. The volatility ratio for the week is 8.64%, and the volatility levels for the past 30 days are at 8.16% for INO. The simple moving average for the past 20 days is 5.75% for INO’s stock, with a -40.24% simple moving average for the past 200 days.

INO Trading at -0.68% from the 50-Day Moving Average

After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.89% of loss for the given period.

Volatility was left at 8.16%, however, over the last 30 days, the volatility rate increased by 8.64%, as shares sank -4.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.12% lower at present.

During the last 5 trading sessions, INO rose by +15.00%, which changed the moving average for the period of 200-days by -78.93% in comparison to the 20-day moving average, which settled at $0.3826. In addition, Inovio Pharmaceuticals Inc saw -74.00% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at INO starting from Zoth Lota S., who sale 5,700 shares at the price of $0.56 back on Jun 05. After this action, Zoth Lota S. now owns 52,716 shares of Inovio Pharmaceuticals Inc, valued at $3,192 using the latest closing price.

Weiner David B., the Director of Inovio Pharmaceuticals Inc, sale 5,833 shares at $1.15 during a trade that took place back on Mar 13, which means that Weiner David B. is holding 910,124 shares at $6,708 based on the most recent closing price.

Stock Fundamentals for INO

Current profitability levels for the company are sitting at:

The net margin for Inovio Pharmaceuticals Inc stands at -2726.67. The total capital return value is set at -79.83, while invested capital returns managed to touch -82.09. Equity return is now at value -81.30, with -56.26 for asset returns.

Based on Inovio Pharmaceuticals Inc (INO), the company’s capital structure generated 14.42 points at debt to equity in total, while total debt to capital is 12.61. Total debt to assets is 9.14, with long-term debt to equity ratio resting at 13.16. Finally, the long-term debt to capital ratio is 11.50.

When we switch over and look at the enterprise to sales, we see a ratio of -121.53, with the company’s debt to enterprise value settled at 0.21. The receivables turnover for the company is 1.04 and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.25.


To put it simply, Inovio Pharmaceuticals Inc (INO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.